This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 1998;279:818.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A genetically engineered vaccine against Escherichia coli O157 tested in a small group of adult volunteers appears safe and stimulates the production of antibodies against the potentially fatal pathogen, researchers reported in the February issue of the Journal of Infectious Diseases.

A vaccine against E coli O157 would be a valuable weapon against the pathogen, because the infection doesn't respond well to antibiotics. Moreover, some researchers believe that antibiotics may increase the incidence of a sometimes fatal complication of the infection, hemolytic uremic syndrome, by promoting the release of a bacterial toxin into the bloodstream.

Researchers at the National Institute of Child Health and Human Development, Bethesda, Md, and the Carolinas Medical Center, Charlotte, NC, tested the vaccine on a group of 87 volunteers, nearly all of whom developed antibodies within 1 week, with no adverse effects other than a mild irritation at the site of . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?